Abbott Laboratories showed strong performance in Q2 2026 with a 4.8% year-over-year sales increase and a 100 basis point rise in adjusted gross margin to 58.0%. Growth was fueled by its acquisition of Exact Sciences for cancer diagnostics, innovative electrophysiology solutions, and a turnaround in its nutrition segment. Despite a valuation-driven downgrade from "Strong Buy" to "Buy," the company is expected to deliver low-teens annual total returns supported by solid fundamentals. Abbott remains a diversified healthcare leader with momentum across key business areas.
Abbott Laboratories reported a strong Q2 performance, beating earnings expectations and raising its full-year guidance. The company's acquisition of Exact Sciences is expected to boost long-term growth, supporting a projected 10.4% compound annual gr...
The National Association of Community Health Centers (NACHC) and Abbott have launched a multi-year "Food for Health" initiative to make nutrition a core part of primary care at over 1,500 Community Health Centers across the U.S. This program includes...
MiniMed has launched its MiniMed Flex system in the U.S., featuring the Instinct sensor made by Abbott. This system is notable for being MiniMed's smallest insulin pump that can be controlled via an app, paired with the world's smallest sensor that l...
